Amylin Pharmaceuticals, Inc and Eli Lilly and Company have entered into a product supply agreement for exenatide once weekly, a development compound that, if approved, would become the first once weekly therapy to treat type-2 diabetes.
The details can be read here.
No comments:
Post a Comment